Combining the scalibility of software startups with biotechnology is a very interesting approach, indeed. Apart from the different timeframe when it comes to working with software and wetware (e.g. lab work with biomaterials), I wonder how easy it will be to get people and know-how on board. In Europe, young scientists (speak: PhD-slaves) are often bound to their research institutes when it comes to the exploitation of the IP generated by their research. They may end up with publications or patents, but usually it is the partners from industry that bring the product to the market. How does this compare to the U.S.?